Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

Clicks: 357
ID: 270460
2017
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #5 of 8 articles by views in The Lancet. Infectious Diseases

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Reference Key
x2017theglecaprevir Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Forns X;Lee SS;Valdes J;Lens S;Ghalib R;Aguilar H;Felizarta F;Hassanein T;Hinrichsen H;Rincon D;Morillas R;Zeuzem S;Horsmans Y;Nelson DR;Yu Y;Krishnan P;Lin CW;Kort JJ;Mensa FJ;;
Journal The Lancet. Infectious Diseases
Year 2017
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.